US pharmaceutical companies are finding that deploying artificial intelligence in European clinical trials means wrestling with a regulatory stack that reaches across multiple directives and agencies. The EU AI Act, medical device rules, data protection law, and sector-specific guidance from the European Medicines Agency now overlap in ways that make compliance a moving target.
The regulatory layers stack up quickly
Since August 2024, the EU AI Act has placed AI systems used for patient screening, treatment recommendations, or safety monitoring in the high-risk category. That classification triggers mandatory conformity assessments, technical documentation, quality management systems, and registration in an EU database before any trial can use the tool.
Pharmaceutical companies also face additional requirements from the EMA. Its 2024 Reflection Paper on AI in drug development calls for transparency around model design, proof that training data represents the intended patient population, and documented human oversight throughout a product’s lifecycle.
If an AI system influences clinical decisions directly, such as determining dosing or patient stratification, it may qualify as a medical device under the MDR. That means parallel certification with separate clinical evidence requirements and post-market surveillance obligations. The GDPR applies concurrently whenever health or genetic data is processed, requiring lawful basis documentation, data protection impact assessments, and compliance with Article 9 rules on sensitive information.
Related: Biotech funding returns as bar rises
The practical result is that a single AI application may simultaneously fall under four distinct regulatory frameworks, each with its own documentation and oversight demands. Companies cannot treat these as separate checklist items.
What European regulators expect from AI systems
The EMA requires trial sponsors to explain exactly how their AI models function. Before launching a European trial, teams must demonstrate training data sources, validate datasets for bias, provide human override controls, and track model performance over time. Legal and ethical responsibility remains with the trial sponsor, not the algorithm.
Under the GDPR, establishing a clear legal basis for processing clinical data has proven tricky. Relying on consent often creates a double consent requirement alongside standard trial participation forms. A proposed EU Biotech Act expected by 2025 aims to resolve this by shifting the legal basis to compliance with a legal obligation, backed by public interest provisions. Until that legislation passes, teams face duplicate paperwork.
Synthetic data has emerged as a way to address both the limited size of clinical datasets and concerns about using real patient information for AI training. The EMA and the AI Act both recognize synthetic data as a valid augmentation technique, though models trained on datasets that fail EU representativeness and bias standards will be rejected outright.
Local interpretation of GDPR across member states adds another layer of complexity. Since 2018, national regulators, data authorities, and ethics boards have taken different positions on sensitive health data. EU law also permits individual countries to impose extra restrictions, creating a patchwork that forces companies to conduct country-by-country legal reviews. The proposed Biotech Act would block this practice under the Clinical Trials Regulation, but that change remains several years away.
Related: Digital Health Pharmacy Practices Indonesia
Six priorities for compliance teams
Companies should begin with an AI risk classification exercise before designing a trial. This determines whether a tool qualifies as high-risk under the AI Act, what data it processes, whether it triggers MDR medical device criteria, and which obligations apply at each regulatory layer.
Building AI governance within GxP-aligned frameworks from the start makes the EU transition substantially smoother. That means version control and model documentation sufficient to reconstruct the full development history, clear validation acceptance criteria, formal change control procedures for any modifications, and full audit trails of AI decisions.
Every company deploying AI systems to process health or genetic data in Europe needs a formal Data Protection Impact Assessment program. The DPIA must address the nature, scope, and purposes of processing, training data provenance and representativeness, automated decision-making risks, technical and organizational mitigations, and residual risk assessment.
The draft Biotech Act allows the European Commission to designate certain EU projects as strategic biotech initiatives, granting access to regulatory sandboxes where teams can build and test AI tools under clear rules. Companies should engage with regulatory authorities early to gain prospective clarity rather than waiting for problems to surface.
Related: Rock the Ring, Rock the World: Finding an Ethical Engagement Ring that Makes a Statement
EDPB Guidelines reaffirm that secondary research benefits from compatibility presumption under GDPR. The draft Biotech Act also permits data reuse across trials by the same controller. US pharma companies should structure data agreements to take advantage of this framework proactively.
The most effective approach treats the regulatory stack as an integrated system rather than separate compliance workstreams. Companies should map GDPR, the AI Act, health data space requirements, and sector-specific rules against each AI system holistically, assigning clear ownership across functions and building compliance triggers directly into the development lifecycle.
What comes next
Several regulatory developments remain in motion. The EDPB continues finalizing guidelines on scientific research and anonymization. The European Health Data Space is taking shape, and reliance on federated research infrastructure is expected to grow. If adopted as proposed, the Biotech Act will fill a critical gap by establishing a clear framework for GDPR-compliant AI in pharmaceutical development.
The January 2026 EMA-FDA joint Guiding Principles show that transatlantic regulators are actively working to align their expectations. For US drugmakers, European AI regulation represents a demanding compliance burden, but companies that invest now in building transparent, well-documented AI pipelines position themselves ahead of competitors still treating regulatory requirements as afterthoughts.
